71 Participants NeededMy employer runs this trial

Wegovy + Mirena for Endometrial Cancer

(WE-FiERCE Trial)

VB
Overseen ByVanessa Ballin
Age: 18 - 65
Sex: Female
Trial Phase: Phase 2
Sponsor: University Health Network, Toronto
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The incidence of endometrial cancer is increasing at an alarming rate. This trend parallels the rising rate of obesity, the most significant risk factor for endometrial cancer. Young women with obesity and endometrial cancer or atypical hyperplasia who want to maintain their fertility are treated with progestin therapy, such as progestin intra-uterine device (pIUD), which is associated with a mediocre response rate and high recurrence rate, and does not address the underlying cause, obesity. Therefore, the investigators want to assess whether the addition of a weight-loss drug to pIUD will improve their oncologic, reproductive and metabolic outcomes.

Who Is on the Research Team?

RS

Rachel Soyoun Kim, MD

Principal Investigator

University Health Network, Toronto

SE

Sarah E Ferguson, MD

Principal Investigator

University Health Network, Toronto

Are You a Good Fit for This Trial?

This trial is for women with early-stage, low-grade endometrial cancer or atypical hyperplasia who are overweight (BMI of 27 or higher), want to preserve fertility, have no spread of disease outside the uterus, and are able to give informed consent.

Inclusion Criteria

My BMI is 27 or higher.
I am fully active or can care for myself with minimal help.
I want to preserve my ability to have children in the future.
See 3 more

What Are the Treatments Tested in This Trial?

Interventions

  • Mirena
  • Wegovy

Trial Overview

The study compares standard hormone therapy using a progestin-releasing IUD (Mirena) alone versus Mirena combined with Wegovy, a weight-loss drug. The goal is to see if adding Wegovy improves cancer treatment and overall health outcomes.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Semaglutide and Progestin Intrauterine DeviceExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

University Health Network, Toronto

Lead Sponsor

Trials
1,555
Recruited
526,000+

GynOncTrials

Lead Sponsor